Sunday, February 28, 2021

TCDA stock: Yahoo -> Finance ->Conversation | March 1, rebound?

 Feb. 28, 2021

It is hard to understand TCDA stock. I like to look into those comments in Yaho -> Finance -> Conversation. 

  1. This stock will get de-listed.
    I purchased it when it dropped from 30 to 15. Then it plummeted to 6. And now again to under 5. This is terrible. If you are risk taker, go ahead and buy. But I recommend avoiding!
  2. Orbimed and Bakers Bros Are still holders ... Dan seems like he thinks he is smarter than the 2 top biotech hedge fund guys out there ...Hmm..
  3. Call prices are super high - over $1 for March $7.5 Market obviously expecting announcement of good news, or at least a high chance of good news at earnings this week (the sudden announcement of earnings was also rather puzzling).
  4. Ahhhh - didn't realize executive options grants were given in January. They normally grant in Feb. LOL.
  5. short term is not look good, may go in 3 or 4 range in next few weeks. Cash in hand will help to move in the long term. Going to accumulate little by little when it falls.
  6. Long term looks great,bright future ahead.....stockwitts
  7. Long wait for results....

    Need to wait till mod 2022 for clinical results so they could resubmit NDA. In the mean time company burns cash. AT the current rate 2/3 of cash will be gone and only 100M next year to be used for manufacturing setup. Net cash will be zero due to debt, so company will need to raise capital...

    Good Luck to all and do your due diligence always...
  8. Orbimed and Bakers Bros are buying more stock today
  9. I will be buying along with Baker Bros and Orbimed ! But you can short if you want ! lol


Watch list: March 1, 2021 | Feb. 26, 2021 Stocks with losses

Feb. 28, 2021

Introduction

It is a new habit for me to build. I like to put together those stocks into my watch list, and I like to look into more and decide if I should invest on those stocks. 

Feb. 26, 2021




The Swedish investor: THE PSYCHOLOGY OF MONEY (BY MORGAN HOUSEL)

Feb. 28, 2021

Here is the link. 

Support the channel by getting The Psychology of Money by Morgan Housel here: https://amzn.to/3aTPV3a As an Amazon Associate I earn from qualified purchases. --- Have you heard the story about Ronald Read, the janitor that had 8 million dollars in savings when he died in 2014? Yes, you heard that right. Janitor. $8 millions. And he didn´t win the lottery or inherit the money either. He just saved consistently throughout his life, while letting the wonders of compounding do its thing. The morale is that your behaviour with money is oftentimes more important than how intelligent you are. Even if you don´t have a diploma from Harvard, or work on Wall Street, you can become rich by just behaving in a sound way. As Morgan Housel puts it: “financial success is not a hard science. It’s a soft skill, where how you behave is more important than what you know.” Spend your next ten or fifteen minutes on this video, and you might excel on the soft skill of investing! This is a top 5 takeaways summary of The Psychology of Money, by Morgan Housel.

Joseph Carlson: The Biggest Danger Facing The Stock Market Right Now | Joseph Carlson Ep. 138

Feb. 28, 2021

Here is the link. 

Famed investors Michael Burry and Cathie Wood have both given grim warnings about the future. In this episode, we discuss those warnings and what we can do with our money to prepare. Patreon: Join my Patreon! You gain access to a discord (an exclusive chatroom) where we talk about investing and stocks daily. I also show every buy and sell I do in real-time. You will also gain access to over 20 exclusive episodes, live streams, and in-depth research on companies. https://www.patreon.com/josephcarlson Joseph Carlson After Hours: https://www.youtube.com/channel/UCfCT... View My Portfolio: https://m1finance.8bxp97.net/Yrb5m M1 Finance (broker used in video): https://m1finance.8bxp97.net/973xy

Equity research and investment: top 10 rules

 Feb. 28, 2021

Introduction

I work with a wechat investment group with 26 people, so I can easily tell my mistakes and know other performance. One has 250% return. I did have over 3000 market loss on my TFSA account. We are all ordinary people, all we can do is to be humble, and work hard, and take small bets, and learn from mistakes. 

Top 10 rules

I do like to think about putting together top 10 rules for an ordinary investor like me, a single 55 year old. 

  1. Do not be greedy. Take profit and run. 
  2. If have time, I should think about 10 baggers or 80 baggers. 
  3. Work on research, learn basics about business, different sectors, all stocks in one sector. 
  4. Learn how to make good project planning and management. 
  5. Learn how to define the position size. 
  6. ...


Sven Carlin: Stock Market News - BUY THE DIP Says JPM + (Inflation, Interest Rates, ARK...)

Feb. 28, 2021

Here is the link. 

Stock Market News on inflation, interest rates, quant flows, buying the dip and long-term investing. 0:00 Stock Market News 0:55 Buy The Dip 2:20 VIX Fear Bubble 4:05 Commodity Supercycle 5:40 Interest Rates 9:57 ARK Invest 13:14 Long-Term Investing ARK Video: https://www.youtube.com/watch?v=-9cak... Voting vs Weighting video: https://www.youtube.com/watch?v=p1Re6... What is this channel all about? Value Investing: https://youtu.be/2GFwfNOKWJM My 5 Core Stock Market Investing Beliefs https://www.youtube.com/watch?v=H_rNn... My passion is to look for low risk high reward investment opportunities with a long-term business owning like focus. I apply my accounting skills and investing experience in order to find the best businesses to own that offer the possibility to lead me towards my financial goals. If you are a sophisticated investor looking for in depth, independent stock analyses and investing ideas, here is my STOCK MARKET RESEARCH PLATFORM (business research and risk reward analysis, stocks to buy from my covered stocks list, my portfolio): https://sven-carlin-research-platform... Here is a bit about how I invested over time, my performance: https://www.youtube.com/watch?v=JGSG3... Are you an investor that is just starting? Sign up for the FREE Stock Market Investing Course - a comprehensive guide to investing discussing all that matters: https://sven-carlin-research-platform... You can download the intrinsic value template for free on my Stock Market Research Platform: https://sven-carlin-research-platform... I am also a book author: Modern Value Investing book: https://amzn.to/2lvfH3t

TOP 10 Pharmaceutical Stocks To Buy 2020 Complete Analysis

Feb. 28, 2021

Here is the link. 

Pharmaceutical stocks have proven to be a safe haven in recessions and with the stock market and economy out of sync now is a great time to look for some smart and safe plays. ► Jerry's Patreon Page & BEAST MODE Spreadsheets: https://www.patreon.com/jerryromine ► WeBull 2 FREE STOCKS VALUE UP To $1400: https://bit.ly/2SRHXOL ► Robinhood Free Stock: https://join.robinhood.com/geraldr567 ► Open A Roth IRA: https://m1finance.8bxp97.net/rmZ5R ► eToro Investing Platform for non-USA to trade in USA: https://bit.ly/36kp6RV


Big pharmaceutical stocks - MRK, BMY, JNJ, ABBY

 Feb. 28, 2021

Introduction

It will take me a few hours to learn basics about top four big pharmaceutical companies. I like to start early as a single 55 year old, and like to learn how to build wealth as a stock investor. 

My first portfolio



Cameron Steward, CFA: AbbVie Inc (ABBV) - Stock Valuation - Estimated Investment Return

Feb. 28, 2021

Here is the link. 


This video is an analysis of AbbVie Inc from the fiscal year 2020 financial results as well as an estimate of the future value and possible investment return based on a discounted cash flow (DCF) and EV / EBITDA market multiple approach. Business Inquires: cashflowinvestingpro@gmail.com Value Investing, Private Equity Valuation, Corporate Finance Valuation, Rational Investing , Cash Flow Investing NYSE: ABBV -- Disclosure -- All opinions expressed by Cameron Stewart on this show are solely Mr. Stewart’s opinions. You should not treat any opinion expressed by Mr. Stewart as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Mr. Stewart’s statements and opinions are subject to change without notice. Past performance is not indicative of future results. Mr. Stewart does not guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this show. Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this show may not be suitable for you. This material does not take into account your particular investment objectives, financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this show. Before acting on information on this show, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.

5 Best Biotech Stocks to Buy for 2021

Feb. 28, 2021

Here is the link. 

These biotech stocks could keep running in 2021 even after a 40%+ gain for the group last year. See how to find the best biotech stocks to watch and how to invest. Follow these and all the stocks in our 2021 Bow Tie Nation portfolio on Stockcard. Use promo code bowtienation for a special discount beyond the free trial! https://mystockmarketbasics.com/stock... Biotech stocks had an amazing year, even beating tech stocks for a 42% return. A rush of investor interest and money into these companies could mean life-changing developments over the next few years and high returns on your investment. But the problem with investing in biotech has always been, how do you analyze these companies if you don’t have a PhD? There’s so much to research here from specific drugs to the FDA approval process, it can be easy to get lost and just want to invest in the biotech ETFs. I like the biotech funds for ideas on stocks but it’s now how you should be investing. Most biotech ETFs just invest passively in the entire group, which means they aren’t analyzing for the best returns. Instead, you need to put together a portfolio of biotech stocks to buy and let them run 3-5 years to see which produce that 5- and 10-times return on your investment. I’ll show you how to narrow your list of stocks and then reveal five biotech stocks to buy for 2021! 🤑 Get The Daily Bow-Tie - my FREE daily email newsletter sharing market updates, trends and the most important news! Market Updates for the Smart Investor! [Sign up Now - Starting January 2020!] https://mystockmarketbasics.com/daily... My Investing Recommendations 📈 📊 Download this Portfolio Tracker and Investing Spreadsheet! [Community Discount Code] https://mystockmarketbasics.com/sprea... Check out the stock simulator and Get a FREE share of stock worth up to $1000 when you open a Webull investing account with a $100 deposit! 🤑 https://mystockmarketbasics.com/webull Follow the 2021 Bow Tie Nation portfolio on Stockcard and get a special 10% discount with promo code: bowtienation https://mystockmarketbasics.com/stock... Free Webinar – Discover how to create a personal investing plan and beat your goals in less than an hour! I’m revealing the Goals-Based Investing Strategy I developed working private wealth management in this free webinar. Reserve your spot now! https://mystockmarketbasics.com/free-... SUBSCRIBE to create the financial future you deserve with videos on beating debt, making more money and making your money work for you. https://peerfinance101.com/FreeMoneyV... Joseph Hogue, CFA spent nearly a decade as an investment analyst for institutional firms and banks. He now helps people understand their financial lives through debt payoff strategies, investing and ways to save more money. He has appeared on Bloomberg and on sites like CNBC and Morningstar. He holds the Chartered Financial Analyst (CFA) designation and is a veteran of the Marine Corps.


钛马领军人-叶志华

 钛马领军人-叶志华

上海交通大学毕业,获工学博士学位。早年曾在日本大福集团 及IBM工作,分别担任总经理助理及汽车咨询服务部总监,为国内十多家汽车企业提供过战略咨询及CRM体系建设服务;之后创办了汽车行业软件公司英孚思为。叶志华博士是汽车信息化领域的知名专家,是智能互联网汽车、客户关系管理、汽车后市场服务三大领域的实战派专家,钛马信息网络技术有限公司董事长、CEO。

Here is the link. 

英孚思为

英孚思为公司主要从事汽车行业应用软件和解决方案的设计、研发及实施、汽车行业业务管理咨询服务、配套计算机软硬件的系统集成及汽车行业IT外包等业务,2009年度实现营业收入9281万元。
公司名称
英孚思为
总部地点
上海
经营范围
汽车行业应用软件
年营业额
9281万元(2009年度)
用友软件(600588)于2010年6月18日发布公告,收购上海英孚思为信息科技股份有限公司。将以4.86亿元的价格收购英孚思为99%的股权,同时全资子公司江西用友以491万元的价格收购另外1%的股权。合计花费4.91亿元购买了100%的股权。
分析与判断:
英孚思为2009年的财务情况是,总资产1.17亿元,负债1088万元,所有者权益1.06亿元;实现营业收入9281万元,净利润2713万元。此次并购的相对价格,按照英孚思为2009年业绩计算为18.1倍市盈率。我们预计英孚思为2010年盈利可增长30%达到3527万元,按照2010年业绩的并购价格为13.9倍市盈率。
英孚思为成立于2003年,核心业务是汽车行业应用软件和咨询,产品包括两大类,面向4S店的管理信息系统及整车生产管理软件,又以面向4S店的信息管理软件为主。英孚思为是国内最大、市场占有率最高的汽车行业DMS软件供应商,客户包括18家车厂、3000多家4S经销商。用友软件原先在汽车行业的产品偏于后端,侧重于财务管理,收购英孚思为后,产品将可实现较好的互补作用。
汽车DMS(经销商管理系统)软件市场规模在2009年为1.95亿元,预计2010年为2.41亿元,未来3年行业增长率约23-25%。按照乘用车品牌的覆盖率英孚思为市场份额居第一,占28.3%,远高于排名第二联友科技的6.7%。
在汽车DCS软件市场,英孚思为市场份额为31.7%,居行业第一,高于排名第二东风联友的6.7%。DCS是汽车企业销售服务管理的核心系统,整车企业需要将DCS系统与汽车经销商的DMS系统进行整合,通常DCS和DMS采用一家软件提供商的产品,从而管控销售服务业务终端的工作情况。
由于较快增长的行业,以及突出的细分行业市场地位,我们预计英孚思为未来3年都将处于较快增长中,平均每年盈利增长率在30%,其中2010年将可增长30%。

Mindset | Poor mindset | Equity research | Short sale squeeze -> biotech stocks

Feb. 28, 2021

Introduction

I like to learn more about biotech stocks since I like to  move away from short squeeze stocks. I did work on GTE and RYCEY stocks in February, and then quickly I bought CRTX and BLUE stock. I make profit on CRTX and BLUE stock over $700 dollars, and I called my SWI and CRTX stocks my ATM machine. I need to take seriously look into my NOK 4500 share position with market value loss over $5000 dollars. I need to learn more about biotech stocks, so that I can handle my greedy issue and learn more about biotech sector as an investor. 

Poor mindset

Stock market is best place for me to seek challenge. I was on track of seeking challenge, I did play hackerrank and got golden medal, and then looked for FANG company, and I had onsite with Microsoft, Amazon, Google and Facebook onsite with Microsoft once, Amazon three time, Google once, Facebook twice. 

I did look into those 80 times return on oil drilling company stock, and then I realized that best place to learn how to do good research is equity research under pandemic special case. 

Biotech - biggest four

I like to spend time for each of those four stocks, and learn something about them. Those stocks are VRTX, NVAX, EXEL and AXSM. 

Poverty mindset | Being low wage or no wage | Stock investment

#GTE #BLUE #CRTX #GTE #RYCEY #NOK #VRTX #NVAX

Feb. 28, 2021

Introduction

I like to learn more about biotech stocks since I like to  move away from short squeeze stocks. I did work on GTE and RYCEY stocks in February, and then quickly I bought CRTX and BLUE stock. I make profit on CRTX and BLUE stock over $700 dollars, and I called my SWI and CRTX stocks my ATM machine. I need to take seriously look into my NOK 4500 share position with market value loss over $5000 dollars. I need to learn more about biotech stocks, so that I can handle my greedy issue and learn more about biotech sector as an investor. 

Poor and struggle

I did not know that I was on track of being poor and struggle over 14 years in United States, with only four year full time working experience and then did not learn how to protect my wealth and let it grow with stock market and other investment. 

Another 10 years from 2010 to 2018 in Canada was wasted, since I did not put wealth building in my top priority. I am a single and I can learn anything about investment by myself. 

Biotech - biggest four

I like to spend time for each of those four stocks, and learn something about them. Those stocks are VRTX, NVAX, EXEL and AXSM. 

#NOK #5000DollarsLoss #StopLoss #LearnStopLoss #BioTech #VRTX #NVAX #Exel #AXSM


May 9 2024

Reviewed the blog and learned a few things. 

Biotech stocks: biggest four

Feb. 28, 2021

Introduction

I like to learn more about biotech stocks since I like to  move away from short squeeze stocks. I did work on GTE and RYCEY stocks in February, and then quickly I bought CRTX and BLUE stock. I make profit on CRTX and BLUE stock over $700 dollars, and I called my SWI and CRTX stocks my ATM machine. I need to take seriously look into my NOK 4500 share position with market value loss over $5000 dollars. I need to learn more about biotech stocks, so that I can prepare for my retirement since I am 55 year old. 

Poor and struggle

I did not know that I was on track of being poor and struggle over 14 years in United States, with only four year full time working experience and then did not learn how to protect my wealth and let it grow with stock market and other investment. 

Another 10 years from 2010 to 2018 in Canada was wasted, since I did not put wealth building in my top priority. I am a single and I can learn anything about investment by myself. 

Biotech - biggest four

I like to spend time for each of those four stocks, and learn something about them. Those stocks are VRTX, NVAX, EXEL and AXSM. 


NOK stock: 4500 shares | Nokia | 5G growth ahead

Feb.28, 2021

Here is the article. 

Highlights: 

  1. Aside from the Jan. 27 short-squeeze from Reddit users that lifted NOK stock to a $9.79 high, the company has no catalysts ahead.
  2. Nokia has 5.61 billion shares outstanding. It could increase its earnings per share by buying back stock. Shares may fall to the $2.34-$3.00 range in the coming months as frustrated investors sell. That gives Nokia a chance to lower the share float at lower costs.



Nokia (NYSE:NOK) is getting left out of the market’s incredibly strong performance. Aside from the Jan. 27 short-squeeze from Reddit users that lifted NOK stock to a $9.79 high, the company has no catalysts ahead.

Nokia’s prospects in the telecom space are not entirely lost. Demand for high-performance networking gear is increasing. Mobile device usage is soaring and internet traffic volumes continue to rise. Nokia management must restructure its business to report higher profit margins.

NOK Stock Fades

Nokia posted good gross margins and revenue in its fourth quarter. The stock failed to get a lift from the report. Strong buying volumes the month before at higher prices will leave a mark on its stock.

Retail investors who overpaid for the stock will look for any opportunity to sell the stock, while long-term investors who missed the chance to sell the stock at between $7 and almost $10 will get frustrated.

Unless it gets a buyout offer, Nokia will lag while the market soars to new highs. Cisco Systems (NASDAQ:CSCO) might offer to buy Nokia for its intellectual property (IP) and 5G positioning. Yet Cisco has its problems.

Cisco failed to capitalize on the telework boom due to the pandemic as Zoom Video (NASDAQ:ZM) ate its lunch. If it had the foresight to develop WebEx for video meetings, its growth would not have stalled.

Patent Revenue

Nokia’s IP is still a cash cow that will give gross margins a lift. Management does not tout its value because of the uneven IP payment schedule.

More recently, BlackBerry (NYSE:BB) reportedly settled a long-lasting legal battle with Facebook (NASDAQ:FB) on the former’s patents. The settlement suggests that companies are now willing to set aside disagreements. Last October, Lenovo (OTCMKTS:LNVGY) lost its case against Nokia. A Regional Court in Munich, Germany, ordered a sales ban on Lenovo’s laptop because Lenovo infringed on Nokia’s video coding patent.

Cases like that imply that Nokia may amass a growing stream of patent revenue. It needs a growing cash flow to invest in the business. Plus, buying back shares, reinstating the dividend, and increasing research and development activities are critical steps in increasing shareholder value.

A growing worldwide ban against China-based Huawei is a one-time opportunity for Nokia. Growing competition in 5G and other wireless technology will encourage a country to protect its domestic companies. As long as the momentum for countries to ban Huawei remains strong, Nokia will have a chance to grow its wireless base station market.

Outlook

Without the Huawei tailwind, Nokia forecasts a strong full-year 2021. Net sales will be between 20.6 billion euro and 21.8 billion euro. The company ended the fourth quarter with a strong liquidity position of 8.1 billion euro in cash and investments. It has no major debt due until 2024 and beyond. The healthy financial positioning suggests that Nokia may take advantage of its low stock price.

Nokia has 5.61 billion shares outstanding. It could increase its earnings per share by buying back stock. Shares may fall to the $2.34-$3.00 range in the coming months as frustrated investors sell. That gives Nokia a chance to lower the share float at lower costs.

As you can see in the chart to the right, Nokia scores fairly well on value.

Nokia’s Capital Markets Day is on March 18. It will assess its dividend policy and update its investors by then. With a short float of only 1.01%, Nokia has no incentive to reinstate its dividend. Investors are not buying the stock for the income potential. They are betting on the growing 5G network upgrade demand lifting revenue.

At a forward price-earnings ratio of around 18 times, Nokia stock is cheap. Investors are better off holding the stock now instead of chasing expensive speculations.

A buyout, a dividend reinstatement, or a surprisingly strong quarter would quickly put an end to the stock’s weak performance.

Saturday, February 27, 2021

SJTU 89 - 92: My SJTU graduate study advisor - Prof Shi

 陈建敏 22:23

我分享一个小故事, 真人真事。当然是表扬我们的老师史老师。

陈建敏 22:29

事情发生在2008年, 已经13年过去了。2008年我在美国工作签证失去工作回中国换成学生签证。年龄四十二岁。我的博士导师有十几个博士, 美国国家自然科学基金兼职做主任。审批国家自然科学基金。我读了四年计算机博士, 实在读不下去。工业届也在美国佛州生存不下去。我决定继续回学校和导师读博士。当年美国经济大萧条, FAU 裁了五个终身教授, 其中一个是计算机教授。

陈建敏 22:33

我在上海交大同班同学忙着给女儿找美国大学。2007年我租了车休假陪她看美国东部几所大学。想读哈佛就是进不去, 当时她女儿才初中。她在日本公司上海做人事经理。交大同学太优秀。简直不敢相信。

陈建敏 22:39

我在交大同学家住了一个晚上, 第二天同学和她先生开车, 把我送到史老师家, 和史老师和师母一起体验上海严冬。那时上海, 现在非常想念。那时上海发展最好阶段。十几年后, 我同学告诉我那年她在浦东买了一套别墅, 空关十几年翻倍了。

陈建敏 22:46

我记得住在史老师家超过三天, 拿到学生签证。去了上海交大徐汇校区。后来过了二年冯xx在美国做教授探访史老师。我才受到提醒赶紧去上海时看望史老师和师母。转眼我来到加拿大11年。98年在佛州和当时室友, 德州陈晓教授去Florida Boynton beach 和史老师见面。

陈建敏 22:51

96年我去佛州留学已经25年。92年毕业后在上海中科院小木桥路和枫林路工作二年, 和史老师和师母见过好几次。非常想念那时上海和中科院同事。

陈建敏 22:53

92年到94年还在史老师另外一个家聚会过一次, 和王xx冯xx。感受上海人美好精致生活。

陈建敏 22:55

我比较喜欢😍热闹。我们大家都分享和史老师和师母故事。那时我们都很年轻。

陈建敏 23:00

也是感谢史老师培养。虽然不是很成功, 但是硕士毕业也轻松留在上海。中科院同事也很优秀。又在706所开西友信息技术公司工作二年。当年人事经理庄xx60多岁, 买了黄浦江旁高层, 三年前回上海我还去看望他和师母。非常亲切。感觉上海有了这些同学和老师, 就是自己第二个家乡。

陈建敏 23:03

我分享这个故事, 感恩我们有这么好母校和同学。还有我的硕士导师和220振动噪声冲击研究所第一份做研究经历。

叶志华 23:06

陈建敏同学,这些故事很有温度,你也一定是发光发热很有温度的人[ThumbsUp]

陈建敏 23:45

我今年已经55岁了。每天在交大投资群里买卖股票, 交大本科同班女同学加州计算机博士broadcom 首席科学家, 一个月前和我们每天交流股票。

陈建敏 23:47

还有上海交大本科加州生物博士, 也在一个小群一起做股票。他儿子读哈佛。我一直做不好大家不听我的。但是大家比较友好, 取长补短。

陈建敏 23:49

我坚持每天语音留言。过一把做老师瘾。没有机会上讲台。

卢卡.Hou.平魁 23:54

@陈建敏,89 to 92 硕 mplighting [ThumbsUp][ThumbsUp][ThumbsUp]

陈建敏 23:59

[App message]


————— 2021-02-27 —————

Bruce 00:01

@陈建敏,89 to 92 硕 mplighting 小木桥路456号?

陈建敏 00:01

是的。我在那住了二年。

陈建敏 00:02

[Voice]

陈建敏 00:03

[Voice]

Friday, February 26, 2021

TFSA | Questrade.com | WealthSimple.com | Feb. 2 - Feb 26, 2021 | RYCEY, GTE.TO, BLUE stocks | 687 US dollars gains

Feb. 26, 2021

Introduction

I like to calculate my gains from Feb. 2 to Feb. 26, 2021. I like to remind myself be humble, work hard on my full time job, spend more time to play sports, and then work on stock investment. Be a better project manager, and learn how to work with others to make progress on stock investment. 

TFSA account 



The investment capital is less than $6000 US dollars. 


BLUE stock position went down with over $300 dollars loss, I should purchase more shares. But I worried about if the price would continue to go down more. I did not purchase more shares of BLUE. 

I said in wechat that I will invest 10,000 shares of GTE.TO, but I actually only purchased 1000 shares of GTE.TO. 



Lessons learned:

  1. I should have paid attention to GTO.TO stock peaked at 1.55/ share. I should have made a plan to maximize my profit, another concern is to add more shares on the stock when the price went up more than 20%. 
  2. I should think about adding more shares on GTE.TO stocks instead of staying on 1000 shares of GTE.TO stock. 
  3. I kept thinking about GTE.TO stock and it will go up to 3 or 4 dollars in summer. But in a short return, I should catch it first, and then build up my gains. I should deal with long term investment later. 





Thursday, February 25, 2021

Investing in the Best Biotech Stocks

Feb. 25, 2021

Here is the article. 

I like to learn more how to invest biotech stocks. It is important for me to spend time to read about biotech basics. 

Biotech basics

What exactly is a biotech? It’s a company that uses living organisms (for example, bacteria or enzymes) to make drugs. This use of living organisms differentiates biotechs from pharmaceutical companies, which use chemicals to develop drugs.

There are four major steps for biotechs in developing new drugs:

  1. Drug discovery, where biotechs identify drug candidates and the diseases that they could potentially target.
  2. Preclinical testing, where biotechs test drug candidates in vitro (in test tubes) and/or in vivo (in living animals, such as mice).
  3. Clinical testing, where biotechs test drug candidates in humans.
  4. Regulatory approval, where biotechs seek to obtain approval from applicable government agencies to sell a drug.

Clinical testing typically involves three phases:

  • Phase 1, which involves small studies designed to find a safe dose for the drug candidate and determine how it affects humans.
  • Phase 2, which involves studies that can include around 100 or more patients and focus on safety, short-term side effects, and determining the optimal dose for the drug.
  • Phase 3, which involves larger studies that can include hundreds or even thousands of patients and that focus on how effectively an experimental drug treats a target disease as well as how safe it is.

A drug candidate must successfully make it through each phase to advance to the next. Once a drug successfully completes a phase 3 trial by demonstrating safety and efficacy in treating the target condition, the biotech will file for regulatory approval using the clinical data from the study. In the U.S., the FDA oversees approvals for new drugs.

Investors should pay close attention to which phases a company’s drug candidates are in. The later the phase, the less risk there usually is. It’s also important to consider a drug candidate’s peak annual sales -- the highest level of sales per year that analysts project. The higher the better.

In addition, a biotech with more experimental drugs in its pipeline (the term used to refer to all a company’s drugs that are in development) will tend to have less risk than a biotech with only one or a very few drug candidates.

Another important thing to watch with biotechs is their financial positions. Most biotechs don’t achieve profitability until they successfully launch one or more drugs in the market. They require significant amounts of cash to fund operations and advance their pipeline candidates. Companies often issue new shares to raise the cash needed, which lowers the value of existing shares. Some biotechs also receive money through partnerships with larger drugmakers and grants from government agencies and nonprofit organizations.

Investment Strategies in Biotech

Feb. 25, 2021

Here is the link. 


System design: WebSockets | HTTP and Websockets: Understanding the capabilities of today’s web communication technologies

 Feb. 25, 2021

Introduction

It is so challenge for me to read articles, since I have to be patient and I am taking shortcuts to learn things by not doing it. I like to learn more about websockets in next few days. Reading is so efficient tool for me to acquire new skills. 

WebSockets 

Here is the link of article on medium.com. 

There are so many classifications for APIs. But when it comes to web communication, we can identify two significant API types — Web Service APIs (e.g. SOAP, JSON-RPC, XML-RPC, REST) and Websocket APIs. But, what do these really mean? Let’s dive into the world of web communication protocols and discuss how to choose the best API mechanisms at the end.

HTTP is the underlying communication protocol of the World Wide Web. HTTP functions as a request-response protocol in the client-server computing model. HTTP/1.1 is the most common version of HTTP used in modern web browsers and servers. In comparison to early versions of HTTP, this version could implement critical performance optimizations and feature enhancements such as persistent and pipelined connections, chunked transfers, new header fields in request/response body etc. Among them, the following two headers are very notable, because most of the modern improvements to HTTP rely on these two headers.

  • Keep-Alive header to set policies for long-lived communications between hosts (timeout period and maximum request count to handle per connection)
  • Upgrade header to switch the connection to an enhanced protocol mode such as HTTP/2.0 (h2,h2c) or Websockets (websocket)